Sign in
Active, not recruitingPhase 2

Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts

Key facts

Who runs it
Rush University Medical Center
Where
Chicago, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
55 people, planned
Started
2 Sept 2025
Expected to end
Jun 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • 9-valent human papillomavirus vaccine
  • Sterile Saline
Record updated
15 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Age 18 years or older
  • Immunocompetent (no history of organ transplantation, active malignancy requiring immunosuppressive therapy, or HIV (human immunodeficiency virus) positive status)
  • At least one wart that has been refractory to treatment
  • At least two treatment modalities failed, including but not limited to:; cryotherapy, electrodesiccation, keratolytic agents, bleomycin, salicylic acid, excision

Who cannot take part

  • Vulnerable populations, including immunocompromised status (active cancer, active tuberculosis (TB) - latent or previous history of these would not exclude patients)
  • Previous severe reaction to HPV vaccination or known allergy to any vaccine component
  • Younger than 18 years of age
  • Unable to provide informed consent
  • Pregnant
  • Prisoner

Where in United States

  • Rush University Medical CenterChicago, United States

About the trial

What the trial wants to find out

This study will evaluate whether Gardasil-9, a vaccine normally used to prevent human papillomavirus (HPV) infection, may be effective for treating recurring warts that have not responded to standard treatments. In this study, Gardasil-9 will be injected directly into a wart rather than into a muscle, which is an investigational use of the vaccine. Participants will be randomly assigned to receive injections of either Gardasil-9 or sterile saline (placebo) directly into a wart. Neither the participant nor the clinician administering the injection will know which treatment is being given. The study will evaluate participants during treatment and follow-up visits to assess their warts and quality of life.

The 2 groups in the trial

  • Intralesional Gardasil-9Treatment being tested

    Participants randomized to this arm will receive 9-valent human papillomavirus (HPV) vaccine (Gardasil-9) administered by intralesional injection into the selected wart or warts. Up to three warts may be treated during a treatment visit. Participants will return approximately every 4-6 weeks for evaluation and may receive additional treatment if the treated wart or warts have not resolved.

    Treatment: 9-valent human papillomavirus vaccine

  • Intralesional Sterile Saline PlaceboPlacebo, for comparison

    Participants randomized to this arm will receive sterile saline administered by intralesional injection as the placebo comparator. Participants will return approximately every 4-6 weeks for evaluation and may receive additional blinded treatment if the treated wart or warts have not resolved. After completion of the blinded study period and disclosure of treatment assignment, participants who received sterile saline will have the option to receive intralesional Gardasil-9 during the open-label extension.

    Treatment: Sterile Saline

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Placebo-Controlled Trial of Intralesional Gardasil-9 Vaccine for the Treatment of Recalcitrant Verrucae
Record updated
15 September 2026